Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.

Nanogen Pharmaceutical Biotechnology

Status and phase

Completed

Phase 3

Conditions

Breast Cancer Female

Treatments

Drug: pegcyte

Drug: Neulastim

Study type

Interventional

Funder types

Industry

Identifiers

NCT03381417

NNG05

Details and patient eligibility

About

Accelerated AC regimen-Doxorubicin 60 mg/m2,Cyclophosphamide 600 mg/m2 on day 1 & day 14 of each cycle along with G-CSF support for up to 4 cycles, followed by Paclitaxel 175 mg/m2 in the next 4 cycles is the standard clinical practice in Vietnam for breast cancer, this regimen is to facilitate the dose-dense schedule, patients receive every-2-week therapy along with G-CSF support. the accelerated dose-dense schedule improve disease-free and overall survival among women with breast cancer .Primary objective of this study is to compare the efficacy and safety of Nanogen's Pegcyte and Roche's Neulastim for prevention of chemotherapy (Accelerated AC regimen)-induced neutropenia on breast cancer patients. Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be recruited in this trial. All eligible patients receive single subcutaneous injection of study drugs 24 hours after chemotherapy administration in each cycle for 3 consecutive cycles. Efficacy and safety assessments will be assessed based on the incidence of severe neutropenia in combination of temperature > 38.3℃ or sepsis or life threatening infection and incidence of serious adverse events.

Enrollment

128 patients

Sex

Female

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Female patients aged between 18 - 65 years.
Patients with histological confirmed primary invasive breast cancer; stage I, II or III.
Patients had no prior chemotherapy treatments.
Patients scheduled to undergo myelosuppressive Doxorubicin and Cyclophosphamide chemotherapy for 04 cycles, and Paclitaxel chemotherapy for the next 04 cycles; patients were available for 14 days of each cycle for the first 03 chemotherapy cycles.
Patients with baseline ANC ≥ 1.5 x 109/L, PLT ≥ 100 x 109/L, HgB ≥ 9 g/dL, WBC ≥ 3,000/mL and albumin ≥ 3.0 g/dL.
Performance status as per ECOG (Eastern Cooperative Oncology Group) score 0, 1 or 2.
Willing to give written and signed informed consent.

Exclusion criteria

Patients with prior exposure of G-CSF or GM-CSF or its pegylated products in clinical development less than 6 months prior to randomization.
Myelotoxic concomitant treatment such as chloramphenicol, methotrexate, immunomodulating agents, interferons during 10 days before randomization.
Received systemic antibiotic treatment within 72 hours of chemotherapy.
Chronic use of corticosteroids, prior bone marrow or stem cell transplant.
Patients who had an immediate/ concurrent exposure to radiotherapy or surgery (within 4 weeks).
Severe medical disease: cardiovascular, hepatic, renal, pulmonary...
Known cases of hematological disease (sickle cell anemia, AML...)
History of HIV positive, active hepatitis.
Pregnant and lactating women or patients planning to become pregnant.
Known allergic reactions to study medications.
Positive to anti-pegfilgrastim antibody test